GWS
IBB icon

Greykasell Wealth Strategies’s iShares Biotechnology ETF IBB Stock Holding History

Greykasell Wealth Strategies’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180K Hold
1,064
– – 0.07% 149
2025
Q4 		$180K Buy
+1,064
New +$173K 0.07% 151

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Greykasell Wealth Strategies's IBB Position: Q1 2026 in Review

Greykasell Wealth Strategies held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 1,064 shares worth $180K. The position accounts for 0.07% of the portfolio, ranked #149.

Greykasell Wealth Strategies first reported a position in IBB in Q4 2025 and has held it in 2 quarters since. 921 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Greykasell Wealth Strategies held 1,064 shares of iShares Biotechnology ETF worth $180K as of Q1 2026.
  • Greykasell Wealth Strategies left its iShares Biotechnology ETF share count unchanged in Q1 2026.
  • iShares Biotechnology ETF made up 0.07% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #149 holding.
  • Greykasell Wealth Strategies first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 2 quarters since.
  • 921 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.